The Potential Protective Effect of Captopril and Irbesartan on Experimentally Induced Non-alcoholic fatty liver in Rats.
|Full paper||Not Available|
the metabolic syndrome including obesity, type 2 diabetes mellitus, hypercholesterolemia and hypertension .Recently, there is accumulating evidence that renin-angiotensin- system (RAS) appears likely to play an important roles in various aspects of the metabolic syndrome. The present study was designed to evaluate the potential hepatoprotective effect of angiotensin converting enzyme inhibitor ACE! (captopril) and angiotensin 11 type 1 receptor blocker ARB ( irbesartan) on high fat diet (HFD) induced fatty liver in male rats. 40 male adult rats were used; rats were separated randomly into 4 groups, ten rats in each group. 1st group is control group was fed with standard chow diet and tap water. 2" group received HFD (1% cholesterol and 10% coconut oil) via oral gavage for 8wks with no medication. 3" group received HFD via oral gavage with oral adminstration of captopri1100mg/kg/day for 8wks. 4thgroup received HFD via oral gavage with oral adminstration of Irbesartan 30mg/kg/day for 8wks. The obtained data in the current work revealed that HFD feeding resulted in significant increase (p<0.05) of serum alanine transaminase (ALT), serum aspartate transaminase (AST) activity, serum total cholesterol (TC), serum triglycerides (TG) and serum low density lipoprotein cholesterol (LDL-c) with significant decrease (p<0.05) of serum high density lipoprotein cholesterol (tDL-c), Albumin/globulin (A/G) ratio, prothrombin time (PT) and serum reduced glutathione (GSH) compared with control group. Hepatic damage was confirmed with histopathological studies. Both captopril and irbesartan treatment decreased serum ALT. AST, TC, TG, LDL-c and increased serum HDL-c, MG ratio and GSH significantly (p<0.05) compared with 1-IFD group, also histopathology of the liver was improved. Captopril affords better hepatoprotective effect as regard liver enzymes, total cholesterol, triglycerides, LDL-c, A/G ratio and liver histopathology, while there was insignificant difference in serum HDL-c and GSH between both drugs. Conclusively: Nonalcoholic fatty liver could be prevented by coadminstration with either captopril or irbesartan suggesting new strategy in prevention and treatement of NASH.